Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Interest ReceivablesChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Cash from Investing Activities: 2024-2025

  • Abivax's Cash from Investing Activities fell 98.30% to $211,676 in Q2 2025 from the same period last year, while for Jun 2025 it was $15.9 million, marking a year-over-year change of. This contributed to the annual value of $16.8 million for FY2024, which is 293.38% up from last year.
  • Abivax's Cash from Investing Activities amounted to $211,676 in Q2 2025, which was down 81.40% from $1.1 million recorded in Q1 2025.
  • Abivax's 5-year Cash from Investing Activities high stood at $12.4 million for Q2 2024, and its period low was $211,676 during Q2 2025.
  • Moreover, its 2-year median value for Cash from Investing Activities was $1.6 million (2024), whereas its average is $4.0 million.
  • Data for Abivax's Cash from Investing Activities shows a maximum YoY slumped of 98.30% (in 2025) over the last 5 years.
  • Over the past 2 years, Abivax's Cash from Investing Activities (Quarterly) stood at $12.4 million in 2024, then slumped by 98.30% to $211,676 in 2025.
  • Its Cash from Investing Activities stands at $211,676 for Q2 2025, versus $1.1 million for Q1 2025 and $12.4 million for Q2 2024.